Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Santini

Showing results (221-230 of 245) with videos related to

Pageof 25
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2011
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancerV Catalano, F Loupakis, F Graziano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2022
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatinR Iacovelli, C Ciccarese, M Brunelli, et al.
ESMO Open|November 3, 2022
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trialsE Dell'Aquila, D Rossini, C A M Fulgenzi, et al.
European Journal of Gynaecological Oncology|December 16, 2004
Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS studyM Branca, S Costa, L Mariani, et al.
ESMO Open|April 16, 2024
ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancerP M Carrera, G Curigliano, D Santini, et al.
ESMO Open|March 6, 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 studyB Borelli, E Fontana, M Giordano, et al.
The Pharmacogenomics Journal|June 6, 2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapyA Ruzzo, F Graziano, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)S Cascinu, F Graziano, F Ferraù, et al.
British Journal of Cancer|February 27, 2015
hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinomaE Lastraioli, G Perrone, A Sette, et al.
Cancer Medicine|March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trialsG Martini, D Ciardiello, V Famiglietti, et al.
Pageof 25

Showing results (221-230 of 245) with videos related to

Sort By:
Pageof 25
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2011
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancerV Catalano, F Loupakis, F Graziano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2022
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatinR Iacovelli, C Ciccarese, M Brunelli, et al.
ESMO Open|November 3, 2022
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trialsE Dell'Aquila, D Rossini, C A M Fulgenzi, et al.
European Journal of Gynaecological Oncology|December 16, 2004
Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS studyM Branca, S Costa, L Mariani, et al.
ESMO Open|April 16, 2024
ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancerP M Carrera, G Curigliano, D Santini, et al.
ESMO Open|March 6, 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 studyB Borelli, E Fontana, M Giordano, et al.
The Pharmacogenomics Journal|June 6, 2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapyA Ruzzo, F Graziano, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)S Cascinu, F Graziano, F Ferraù, et al.
British Journal of Cancer|February 27, 2015
hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinomaE Lastraioli, G Perrone, A Sette, et al.
Cancer Medicine|March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trialsG Martini, D Ciardiello, V Famiglietti, et al.
Pageof 25